Publication at Second Faculty of Medicine |
2020
Abstract
Despite the advantageous pharmacokinetic/pharmacodynamic properties of short-actinginsulin analogues compared to human insulins, there is a need for an even more physiological profile in postprandial glycaemic control. Fast insulin aspart (Fiasp) solved a number of problems, yet we hear complaints from our patients of the following type: not very fast, startsacting later, late hypoglycaemia after a meal, severe fall after injection.
However, a new ultrafast insulin lispro brings further approximation to physiological prandial insulin secretion compared to available short-acting insulin analogues.